Annexon Biosciences

2 followers


Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye.

Org chart

Douglas Love
President & Chief Executive Officer

Douglas Love

Collapse
Michael Overdorf
EVP & Chief Business Officer
Rick Artis
Chief Scientific Officer
Jennifer Lew
EVP & Chief Financial Officer
Ted Yednock
EVP & Chief Innovation Officer
Dean Richard Artis
EVP And Chief Scientific Officer
Jamie Dananberg
EVP & Chief Medical Officer
AJ Acker
Senior Vice President, Regulatory, Quality & Clinical Safety
Behn Sarafpour
Vice President Medical Affairs
Cecilia Oliyai
Senior Vice President CMC Operations
John Hanna
VP & Head of Clinical Safety
Peter Collins
Vp, Global Program Team Lead - Neurodegeneration Franchise
Henk-Andre Kroon
Svp, Head Of Translational Medicine
Kunal Kanani
Vice President Regulatory Affairs
Ping Lin
Senior Director, Head Of Biostatistics
Ranjith K.
Director, Head Of Statistical Programming